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The authors of this text should be applauded for aiming to provide
a comprehensive chemotherapy protocol book and easy reference
text for the practicing oncologist. Do they achieve their goal? They
have certainly provided a broad compilation of the majority of
commonly used chemotherapy protocols for malignant disease,
which will serve as a good reference text in oncology departments.
The book has an interesting and unusual style and format. There
is a short introductory section entitled ￿General Principles￿, which
covers supportive therapy, and toxicity and administration guide-
lines. I found this section suffered from being too brief. The authors
should have been able to cover toxicity and administration for all
the commonly used cytotoxic drugs in some detail. In the
supportive therapy section, there are some idiosyncrasies of treat-
ment with which I would not necessarily agree. Unfortunately,
because the book is not referenced in the conventional way, it is not
possible to access the source easily and examine the evidence for
the guidelines. For example, in the treatment of extravasation of
vesicant cytotoxic drugs, the authors suggest using 99% dimethyl
sulphoxide four times daily for 2 weeks and reference a random-
ized study in rats. These recommendations would certainly not be
current standard practice in oncology centres, but if it is true, we
need to see the evidence for it so that improvements in practice can
be introduced. For the commonly used drugs some important infor-
mation is emphasized, which will guide good clinical practice, but
in my view, this section should have been more comprehensive.
The main section of the book itemises the majority of protocols
used over the past 25 years. In the larger chapters (e.g. on breast
cancer) it is difficult to discover how the protocols have been
ordered, although the sequence seems to be more or less chrono-
logical. It would be helpful to know whether there is anything
more significant about the order in which the protocols are
presented, because it would enable the reader to give some sort of
￿weighting￿ to each. The comments sections are on the whole very
useful, giving information on response rates and some important
comparisons with other protocols, together with a reference for
each protocol.
There are some inaccuracies and omissions. For example, the
AC regimen listed for breast cancer is not the one that most prac-
ticing oncologists would recognize or frequently use. The single
agent activities listed at the beginning of each chapter are useful
but, unfortunately, some contain inaccuracies, e.g. to ascribe
cisplatinum a single agent response rate of only 27% in ovarian
cancer is incorrect. In the section on osteosarcomas in protocols
using high-dose methotrexate, the folinic acid rescue regimens are
unclear and, despite the fact this is covered in the introductory
section, this is of such importance that I think it should be empha-
sized within each protocol using high-dose methotrexate. In the
section on Ewing￿s sarcoma, the now commonly used IVAD/IVA
and EVAIA protocols are not included — which they should be for
this rare tumour. There are some inaccuracies in the section on
non-small-cell lung cancer, soft tissue sarcomas and osteosarcoma
which could be a little more serious if attempts were made to
implement them by practicing oncologists. Discrepancies between
this book and the clinical papers it cites could lead patients to be
over- or under-treated.
As a comprehensive reference book and short guide to the
majority of chemotherapy protocols, this book works well enough
and will find a place as a reference book in oncology pharmacies
and oncology libraries, and on the shelves of practicing oncolo-
gists. However, despite the disclaimer by the authors and
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This book is the second edition of a book which aims to cover all
aspects of lung cancer. It has been updated over the last 5 years
and edited by authors from the MD Anderson Cancer Centre,
Texas, USA.
This book would aim to pitch itself as an intermediate work of
reference, i.e. it should be a source of information more detailed
than a general oncology textbook but fall short of the most recent
advances in lung cancer which by their very nature would have to
be published in peer reviewed journals. There are 20 chapters that
cover most areas of lung cancer. A large number of chapters focus
on developing strategies in lung cancer such as molecular and
fluorescent detection, chemoprevention, lung cancer genetics and
growth factor and biologic approaches to therapy. The more stan-
dard treatment modalities for lung cancer, such as surgery, radio-
therapy and chemotherapy, are covered but there are some notable
omissions which will be discussed later.
The early chapters include the biology of pre-neoplastic
regions, and give a very detailed and good historical background
to the subject. In particular, there is a good summary of the
chromosomal abnormalities present and some discussion on how
multistage carcinogenesis may apply in this disease. The chapter
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